Table 2 Most common regimens used across index and subsequent LOT.

From: LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

LOT

Number of unique regimens

Most common regimens,a (%)

Index LOT

91

Kd (14.1), CPd (14.1), Pd (11.7)

1st Subsequent LOT (n = 152)

78

blmf (10.5), PCd (6.6)

2nd Subsequent LOT (n = 74)

47

blmf (18.9), KCd (5.4), Kd (5.4)

3rd Subsequent LOT (n = 42)

30

blmf (19.0), IsaPd (11.9), DKd (4.8)

≥4th Subsequent LOT (n = 17)

34

blmf (17.6)

  1. blmf belantamab mafodotin, PCd pomalidomide, cyclophosphamide, and dexamethasone, DKd daratumumab, carfilzomib, and dexamethasone, IsaPd isatuximab, pomalidomide, and dexamethasone, KCd carfilzomib, cyclophosphamide, and dexamethasone, Kd carfilzomib and dexamethasone, LOT line of therapy, Pd pomalidomide and dexamethasone.
  2. aPatients can be counted in >1 regimen per LOT.
Back to article page